HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gemini Cosmetics

This article was originally published in The Rose Sheet

Executive Summary

Tommy Bahama marketer announces appointment of four new executives, effective immediately. Jacqueline Singer will assume the role of VP-marketing. Singer most recently worked at Coty as group marketing director of global fragrances, and also has held positions with Estee Lauder International and Lancôme. Gemini Cosmetics was founded earlier this year by former Liz Claiborne execs Neil Katz and Robert Rumsby, and several Claiborne veterans are joining the company, including Craig Ahlheim as VP-sales, Sam Endy as CFO and treasurer and Kristin Finn as director- marketing and sales administration. Gemini will launch its first products, Tommy Bahama fragrances for men and women, in February (1"The Rose Sheet" July 12, 2004, p. 7)...

You may also be interested in...

Gemini Cosmetics Heads To The Tropics For First Fragrance Launch

Gemini Cosmetics will unveil its first offering next spring with the launch of a Tommy Bahama signature scent, President and CEO Neil Katz said. The new firm, founded by two former Liz Claiborne Cosmetics execs, announced a licensing agreement with the tropical lifestyle company July 8

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts